Sign in Subscribe
Child health

New Findings in Remdesivir Therapy from Yonsei University

Strategic Insights

— 1 min read

Researchers at Yonsei University in South Korea have made new discoveries regarding the effectiveness of Remdesivir in treating COVID-19, particularly in pediatric patients. According to a recent study, a unique SARS-CoV-2 strain, designated N15, was isolated from a pediatric nasal swab and found to replicate efficiently in Vero cells, making it a valuable reference strain for comparative studies.

Key Takeaways:

  • The pediatric N15 isolate, a SARS-CoV-2 strain, was successfully isolated from a pediatric nasal swab and found to replicate efficiently in Vero cells, with kinetics comparable to B.1 and B.1.1.529 lineages.
  • The isolate was classified within lineage 19B, showing 99.9% similarity to the Wuhan-Hu-1 strain, and harbored rare mutations, including N709S in the spike protein and T11M in the E protein.
  • Antiviral testing revealed effective inhibition by Remdesivir, Molnupiravir, and Nirmatrelvir, with varying IC50 values across cell types.
  • The N15 isolate represents a unique 19B lineage virus, retaining ancestral genomic features while harboring rare mutations.
  • The efficient replication and drug sensitivity of the N15 isolate underscore its value as a reference strain for comparative studies against circulating variants and for evaluating antiviral efficacy.
  • Additional research authors include Hee Chun Chung, Su Jin Hwang, Sung Hoon Park, Hyeon Woo Chung, Si Hwan Ko, Sung Jae Kim, Kyoung Min Park, Dong il Park, Jun-Yeop Shim, and Van Giap Nguyen.
  • Financial supporters for this research include the Korea Science and Engineering Foundation and the National Research Foundation of Korea.

Statistics:

  • The isolate was isolated from a pediatric nasal swab.
  • The isolate was found to replicate efficiently in Vero cells.
  • The isolate was classified within lineage 19B.
  • The isolate showed 99.9% similarity to the Wuhan-Hu-1 strain.
  • The isolate harbored rare mutations, including N709S in the spike protein and T11M in the E protein.
  • Antiviral testing revealed effective inhibition by Remdesivir, Molnupiravir, and Nirmatrelvir, with varying IC50 values across cell types.

Sources:

  • Medical Letter on the CDC & FDA, 2025; p 349 (NewsRx).
  • Frontiers in Microbiology, 2025;16 (Frontiers Media SA, Avenue Du Tribunal Federal 34, Lausanne, CH-1015, Switzerland).
  • Isolation of a Sars-cov-2 Strain From Pediatric Patients In South Korea: Biologic and Genetic Characterization (Jae Myun Lee, Yonsei University, Inst Immunol & Immunol Dis, College of Medicine, Dept. of Microbiology and Immunology, Seoul, South Korea).

Read more